Floatz Rating
B58/100
Confidence
Indicative
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
43Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01063868CT.gov A Long-term Safety Study With Tapentadol ER and Oxycodone CR in Patients With Moderate to Severe Pain Due to Chronic, Painful Diabetic Peripheral Neuropathy (DPN) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Diabetic Polyneuropathy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Tapentadol (this asset) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P3 | B · 58 |
| Duloxetine | University of Rochester | P4 | BB |
| Pregabalin | Syeda Khatoon e Jannat Welfare Foundation | P4 | BB |
| (±)-Tramadol | Turku University Hospital | P4 | BB |
| Capsaicin | Thammasat University | P2/3 | B |
| Adezunap | Apurano Pharmaceuticals GmbH | P3 | B |
| Oxycodone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | P3 | B |
| Cebranopadol | Tris Pharma, Inc. | P2 | B |
| Sofinicline | AbbVie (prior sponsor, Abbott) | P2 | B |
+12 more in the Diabetic Polyneuropathy cohort
Other indications for Tapentadol
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Osteoarthritis | — | P4 | BB · 71 |
| Vertebral Column Disorder | — | P4 | BB · 67 |
| Diabetic Neuropathy | — | P3 | BB · 65 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Tapentadol in Diabetic Polyneuropathy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/tapentadol-diabetic-polyneuropathy
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →